Clinical Trials

Key Inclusion Criteria:

- Has a Karnofsky performance scale (KPS) score ≥ 70 at screening.

- Has a diagnosis of GBM (WHO GRADE III or Grade IV GBM) based on the treating
neurosurgeon's best clinical judgement.

- Has a diagnostic contrast-enhanced magnetic resonance imaging (MRI) scan with fluid
attenuated inversion-recovery (FLAIR) sequence of the brain at screening. Participants
must have a confirmed measurable disease (as assessed by the adapted Response
Assessment in Neuro-Oncology [RANO] criteria) pre-operatively with at least 1 lesion
measuring a total bi-perpendicular product of 4 centimeter square (cm^2) in 2
different planes (axial, sagittal, or coronal).

- The tumor must be located in the supratentorial compartment.

- Tests positive for at least 1 antigen for Candida or trichophyton from the anergy
panel at screening.

- Has adequate bone marrow and organ function at screening.

Key Exclusion Criteria:

- Has bi-hemispheric disease, multicentric disease, or disease burden involving the
brain stem or cerebellum based on MRI post-gadolinium enhancement.

- Has received any previous surgical resection or any anticancer intervention for GBM.

- Has recurrent glioma, a concurrent malignancy, or malignancy within 3 years of
randomization, unless definitive therapy is completed, with the exception of basal or
squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the
cervix or breast that has completed curative therapy.

- Has any severe immunocompromised condition (eg, a cluster of differentiation [CD] 4
cell count < 200 *10 ^6/liter [L]) or any active uncontrolled autoimmune disease (eg,
Crohn's disease).

- Has an active cardiac disease or a history of cardiac dysfunction.

- Is receiving any other investigational agent(s) or has received an investigational
agent within 30 days or 5 half-lives, whichever is longer, prior to screening.

- Is partaking in another interventional study. Participants who are partaking in an
observational study are eligible.

- Has received a live vaccine within 30 days of screening.

- Tests positive for hepatitis B virus, hepatitis C virus, human immunodeficiency virus,
or any other active infections that, in the Investigator's opinion, would impair or
prohibit a participant's involvement in the study.

- Is receiving treatment with Tumor Treating Fields or Optune®.